Drugs / PM1032
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05839106 | Jul 2022 → Apr 2025 | — | BioNTech SE | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PM1032 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05839106 ↗ |
| Route | Intravenous | “Subjects will receive PM1032 by intravenous administration.” NCT05839106 ↗ |
| Target | CLDN18 | “PM1032 is a Bispecific Antibody Targeting CLDN18.2 and 4-1BB.” NCT05839106 ↗ |